

Nexstim

Nexstim Receives NBS System 5 Order in Europe

Press release, Helsinki, 5 October 2023 at 9 AM (EEST)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 5 system. The end user is a new neurosurgery customer located in Europe.

Nexstim's NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the speech and motor cortices of the brain. In addition to its motor and speech mapping features, this specific system also includes therapeutic capabilities that allow the system to be used for the treatment of major depression and chronic neuropathic pain.

Mikko Karvinen, CEO of Nexstim, comments: *"Functional nTMS (navigated transcranial magnetic stimulation) mapping provides accurate information on the anatomic relationship of the surgical targets with essential functions in the brain. This makes our technology a desired solution for neurosurgeons. Our combined system option extends the benefit by offering multi-departmental utilization possibilities."*

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com